Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gavis Pharmaceuticals LLC

Division of Lupin Ltd.
www.gavispharma.com

Latest From Gavis Pharmaceuticals LLC

Profile: Lupin CFO Swaminathan, The ‘Constant Learner'

CFOs are known for talking about their top and bottom lines, but not so much about what makes them tick. Here we give you a peek into the life story of Lupin CFO Ramesh Swaminathan, who shares with Scrip why he made the shift from Henkel in Germany to the Indian firm, M&A learnings, admiration for peer Sun Pharma and his own career ambitions.

 

Commercial Companies

Lupin Slumps To Q4 Loss Amid US Opioid Action But Build Up In Inhalation, Biosimilars

Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.

Commercial Strategy

Lupin Primes For Specialty Future With Symbiomix Acquisition

Lupin has snapped up Symbiomix Therapeutics in the US as it evolves its business from a predominantly straight-generics play to a model with an increasing mix of complex generics, specialty medicines and biosimilars. The latest deal gives Lupin access to a therapy in the women’s health segment recently approved by the US FDA.

M & A Strategy

Lupin Primes For Specialty Future With Symbiomix Acquisition

Lupin has snapped up Symbiomix Therapeutics in the US as it evolves its business from a predominantly straight-generics play to a model with an increasing mix of complex generics, specialty medicines and biosimilars. The latest deal gives Lupin access to a therapy in the women’s health segment recently approved by the US FDA.

M & A Strategy
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lupin Ltd.
  • Senior Management
  • Veerappan Subramanian, PhD, Chmn. & CEO
    Kevin Anderson, VP, Sales & Mktg.
    Arshad Kagalwalla, VP, Fin. & Accounting
    James Garegnani, Dir., Prod. Dev.
    Tammy M Stefanovic, President
    Scott Talbot, VP, QA & Regulatory
    Bala Nayar, PhD, VP, Specialty Product dev
    Swapan Roychowdhury, Director, Analytical R&D and QC
    Dmitriy Kalika, Director, MIS
    Aman Trehan, PhD, Director, IP
  • Contact Info
  • Gavis Pharmaceuticals LLC
    Phone: (908) 603-6080
    400 Campus Drive
    Somerset, NJ 08873
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register